Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 90.66% | -7.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 90.66% | -7.40% | |||
| Cost of Revenue | -64.94% | 12.47% | |||
| Gross Profit | 140.02% | -12.32% | |||
| SG&A Expenses | 5.56% | -6.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.05% | -0.93% | |||
| Operating Income | 378.38% | -23.31% | |||
| Income Before Tax | 421.08% | -24.38% | |||
| Income Tax Expenses | 467.69% | -92.62% | |||
| Earnings from Continuing Operations | 420.82% | -20.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 420.82% | -20.19% | |||
| EBIT | 378.38% | -23.31% | |||
| EBITDA | 361.31% | -22.49% | |||
| EPS Basic | 418.61% | -20.92% | |||
| Normalized Basic EPS | 418.84% | -25.06% | |||
| EPS Diluted | 420.63% | -20.99% | |||
| Normalized Diluted EPS | 421.24% | -25.14% | |||
| Average Basic Shares Outstanding | 0.43% | 0.91% | |||
| Average Diluted Shares Outstanding | -0.04% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||